This report examines the alarming methodological and contextual shortcomings of the Quality Adjusted Life Years (QALY)-based methodology in evaluating new cancer therapies. It reveals five specific problems with ICER’s evaluation of cancer treatments and demonstrates the urgent need to prohibit the use of the QALY amid trends in rapid cancer innovations and personalized medicine.
https://pioneerinstitute.org/wp-content/uploads/The-QALY-and-Cancer-Treatments_-An-Ill-Advised-Match.png5121024William Smithhttps://pioneerinstitute.org/wp-content/uploads/logo_440x96.pngWilliam Smith2021-04-06 06:00:112021-12-29 12:22:15The QALY and Cancer Treatments: An Ill-Advised Match
Pioneer Institute today released a new analysis, The QALY and Cancer Treatments: An Ill-Advised Match, that examines the alarming methodological and contextual shortcomings of the Quality Adjusted Life Years (QALY)-based methodology in evaluating new cancer therapies. The Pioneer Institute analysis reveals five specific problems with ICER’s evaluation of cancer treatments and demonstrates the urgent need to prohibit the use of the QALY amid trends in rapid cancer innovations and personalized medicine.
https://pioneerinstitute.org/wp-content/uploads/The-QALY-and-Cancer-Treatments_-An-Ill-Advised-Match.png5121024Editorial Staffhttps://pioneerinstitute.org/wp-content/uploads/logo_440x96.pngEditorial Staff2021-04-06 04:45:242021-07-19 10:41:05New Analysis: ICER Framework Ignores Patient Preferences, Innovation & Societal Benefits in Evaluating Cost-Effectiveness of New Cancer Treatments
https://pioneerinstitute.org/wp-content/uploads/The-QALY-and-Cancer-Treatments_-An-Ill-Advised-Match.png
512
1024
William Smith
https://pioneerinstitute.org/wp-content/uploads/logo_440x96.png
William Smith2021-04-06 06:00:112021-12-29 12:22:15The QALY and Cancer Treatments: An Ill-Advised Match